A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer

Status: Recruiting
Phase:
Diagnosis: Lung Cancer
NCT ID: NCT01121575 (View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 10-168

 

Lung cancer tumors become resistant to the first generation epidermal growth factor receptor (EGFR) inhibitors erlotinib or gefitinib by changing and increasing the activity of two cell signaling pathways: the cMET pathway and the EGFR pathway. Both resistance mechanisms can occur at the same time, in the same patient and even in the same tumor. This study combines a second generation EGFR inhibitor and a cMET inhibitor to block both these pathways in order to overcome resistance and treat this disease.

 

Conducting Institutions:
Brigham and Women's Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital

Overall PI:
Jeffrey Engelman, MD, PhD, Massachusetts General Hospital

Site-responsible Investigators:
Pasi Janne, MD, PhD, Dana-Farber Cancer Institute

Contacts:
Massachusetts General Hospital: Cancer Trials Call Center, 877-789-6100
Dana-Farber Cancer Institute: Kelly Masone, 617-632-3383, kmasone@partners.org

Eligibility Criteria

Inclusion Criteria: - advanced non small cell lung cancer (dose escalation phase) - acquired resistance to erlotinib or gefitinib (expansion phase) - mandatory entrance biopsy (expansion phase) Exclusion Criteria: - interstitial lung disease - unstable brain metastases - leptomeningeal disease
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms